Nurix Therapeutics, Inc. — Form 10-Q Summary
Period clarification: The supplied filing is for the three months ended February 28, 2022, Nurix’s fiscal first quarter of 2022, not 2021 Q1. It was filed April 8, 2022. Unless otherwise noted, financial amounts are in millions of dollars.
Business context and reporting period
Nurix is a clinical-stage biopharmaceutical company developing small-molecule and cell therapies using its DELigase platform. Its wholly owned clinical programs include NX-2127 and NX-5948, BTK degraders; NX-1607, a CBL-B inhibitor; and DeTIL-0255, a cell therapy candidate. It has no approved products and has not generated product-sales revenue. Collaboration revenue comes primarily from agreements with Gilead and Sanofi.
Financial results and liquidity
| Metric | Q1 FY2022 | Q1 FY2021 |
|---|---|---|
| Collaboration revenue | $9.6 | $5.0 |
| Research and development expense | $43.1 | $23.0 |
| General and administrative expense | $9.2 | $6.5 |
| Total operating expenses | $52.4 | $29.5 |
| Operating loss | $(42.7) | $(24.5) |
| Net loss | $(42.5) | $(24.3) |
| Basic and diluted loss per share | $(0.95) | $(0.63) |
| Net cash used in operating activities | $(42.6) | $8.1 provided |
Cash, cash equivalents and investments totaled $385.7 at February 28, 2022. Cash, cash equivalents and restricted cash were $79.7. Total assets were $437.7; total liabilities were $131.8, including $15.8 of operating lease liabilities and $98.6 of deferred revenue. The filing reports no interest-bearing borrowings. Accumulated deficit was $263.4. Management stated available cash, cash equivalents and investments were expected to fund operations for at least 12 months after issuance of the statements.
There was no meaningful product gross margin because Nurix had no product sales; the filing does not provide a product-margin measure. Collaboration revenue was recognized over research obligations, with milestone-related catch-up adjustments.
Changes versus the comparable period
- Revenue increased $4.6, mainly from milestone-related cumulative catch-up revenue and greater progress on Gilead and Sanofi research obligations.
- R&D expense rose $20.1, driven by increased headcount and stock compensation, research and laboratory supplies, manufacturing, and clinical-trial start-up and enrollment costs.
- G&A expense rose $2.7, including higher stock compensation, staffing and professional services.
- Net loss widened $18.3. Operating cash flow moved from $8.1 provided to $42.6 used, reflecting operating losses and working-capital changes.
- Available-for-sale investments recorded $1.5 of unrealized losses in other comprehensive loss. Total comprehensive loss was $44.0.
Outlook, risks and unusual items
- Management expects expenses to increase as clinical trials, discovery programs, manufacturing capacity, staffing and public-company costs expand. It expects no product revenue unless candidates are developed and approved, a process that may take years, if successful.
- Nurix said its four lead candidates were in Phase 1 trials and anticipated advancing them toward Phase 1b trials in 2022; the filing provides no financial guidance or specific revenue forecast.
- Potential collaboration economics are substantial but contingent: Nurix disclosed eligibility for up to approximately $2.3 billion of additional Gilead payments and $2.5 billion of Sanofi payments, plus potential royalties. These amounts depend on milestones, options and other conditions and are not assured.
- Gilead research milestone revenue of $6.0 was received in the second fiscal quarter of 2022; a $2.0 Sanofi milestone recognized in February was expected to be paid in that quarter.
- Key risks include early-stage clinical and regulatory uncertainty, adverse events, patient enrollment, competition, intellectual-property challenges, reliance on third-party and in some cases single-source manufacturers, collaborator decisions, financing needs and possible COVID-19-related disruption. Management said COVID-19 had not materially affected the quarter’s statements, but future effects were uncertain.
- Disclosure controls were deemed ineffective as of February 28, 2022 because previously identified material weaknesses in IT general controls and segregation of duties had not been remediated. Management reported no resulting financial-statement misstatement and said it performed additional review procedures; remediation remained ongoing.
- After quarter-end, Nurix entered a lease for about 46,434 square feet in Texas, expected to commence around August 1, 2022 and run through March 1, 2035. Minimum monthly rent begins in 2023; additional operating, tax and utility costs also apply.
- No material legal proceedings were reported. The company also disclosed a California tax audit dispute over revenue sourcing and R&D credits; it intends to challenge proposed assessments.
Important facts for investors to verify
- Confirm the reporting period: the filing covers fiscal Q1 2022, ended February 28, 2022, despite the request metadata saying 2021 Q1.
- Track cash burn and collaboration receipts against the stated 12-month runway, and assess the timing and terms of any future financing or ATM share sales.
- Monitor clinical-trial progress, safety, enrollment and any announced milestones for NX-2127, NX-5948, NX-1607 and DeTIL-0255.
- Verify whether the Gilead and Sanofi milestone payments were received as anticipated and distinguish contingent milestone ceilings from committed funding.
- Follow remediation and independent testing of the disclosed material weaknesses in financial reporting controls.
- Assess the financial impact of the new Texas lease and the company’s dependence on third-party manufacturers and suppliers.